Description and references

Non-steroidal anti-inflammatory with long half-life. Prepn (keto form): J. Lombardino, DE 1943265; idem, US 3591584 (1970, 1971 to Pfizer). Synthesis and biological properties: J. Lombardino, E. Wiseman, J. Med. Chem. 15, 848 (1972); J. Lombardino et al., ibid. 16, 493 (1973). Characterization of crystal modifications: F. Vrecer et al., Int. J. Pharm. 256, 3 (2003). HPLC determn in plasma: S. Dadashzadeh et al., J. Pharm. Biomed. Anal. 28, 1201 (2002). Pharmacology: E. Wiseman et al., Arzneim.-Forsch. 26, 1300 (1976). Evaluation of ulcerogenic effects: G. Palacios et al., Methods Find. Exp. Clin. Pharmacol. 9, 353 (1987). Antitumor effects in canine squamous cell carcinoma: B. R. Schmidt et al., J. Am. Vet. Med. Assoc. 218, 1783 (2001). Review of pharmacology and therapeutic efficacy: R. N. Brogden et al., Drugs 22, 165-187 (1981); eidem, ibid. 28, 292-323 (1984). Symposium on clinical efficacy and safety: Am. J. Med. 81, Suppl. 5B, 1-55 (1986). Comprehensive description: M. Mihalic et al., Anal. Profiles Drug Subs. 15, 509-531 (1986). Review of therapeutic potential of β-cyclodextrin complex: C. R. Lee, J. A. Balfour, Drugs 48, 907-929 (1994).

Properties

Derivative

Derivative